Adcentrx Therapeutics, a San Diego, CA- and Shanghai, China-based biotechnology company dedicated to developing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, extended ints Series A+ financing to $51M.
The Series A+ extension of $13M included participation from Quan Capital and Partners Investment.
The company intends to use the funds to continue advancing its propriety ADC therapeutic pipeline in the clinic.
Led by Hui Li, Ph.D., Founder and CEO, Adcentrx is a biotechnology company focused on the protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting small molecule payloads, Adcentrx plans to develop targeted therapies for improving patient treatment options.
ADRX-0706 is an ADC product candidate discovered by Adcentrx. The antibody component targets Nectin-4, a cell surface adhesion protein over-expressed in multiple human cancers and associated with poor disease prognosis. The ADC is produced using Adcentrx’s proprietary i-Conjugation™ technology and novel tubulin inhibitor payload, AP052, to generate an ADC with a drug-antibody ratio of eight (DAR 8). ADRX-0706 has a favorable pharmacokinetic and safety profile in preclinical models, and has demonstrated significant efficacy across a variety of tumor indications. ADRX-0706 is currently being evaluated in a Phase 1a/b clinical trial.
FinSMEs
06/12/2023